In both pediatric and adult NAFLD patients, clinical trials including species of Lactobacillus and Bifidobacterium have shown increases in liver enzyme levels, decreases in hepatic fat content, as well as improved insulin sensitivity [92,93,94]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.